Abstract
Currently, immune checkpoint blockade against members of the B7/CD28 family is being used as a new molecular-targeted therapy, in patients with unresectable advanced or recurrent gastric cancer. Although human endogenous retrovirus-H long terminal repeat-associating protein 2 (HHLA2) is a novel molecule of the B7/CD28 family, the clinical impact of its expression remains uncertain in gastric cancer. Consequently, we examined HHLA2 expression in blood specimens from patients with gastric cancer, and investigated the relationship between its expression and clinicopathological factors to assess its potential power as a prognostic blood predictor. Untreated peripheral blood specimens were obtained from 111 patients with gastric cancer and 20 healthy volunteers. HHLA2 mRNA expression levels were determined using quantitative RT-PCR assay. Blood specimens obtained from patients with gastric cancer had significantly lower copies of HHLA2 mRNA than those obtained from healthy volunteers (P < 0.0001). Furthermore, HHLA2 expression was significantly correlated with the depth of tumor invasion (P = 0.0331), distant metastasis (P < 0.0001), and stage of disease (P = 0.0032). The 5-year survival rate was significantly higher in patients wit...Continue Reading
References
Aug 13, 1999·Genomics·D L MagerJ D Freeman
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Sep 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xingxing Zang, James P Allison
Feb 20, 2008·The Lancet Oncology·Wasaburo KoizumiMasahiro Takeuchi
Aug 24, 2010·Lancet·Yung-Jue BangUNKNOWN ToGA Trial Investigators
Jan 22, 2011·Cancer Science·Takaaki ArigamiShoji Natsugoe
May 17, 2011·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·UNKNOWN Japanese Gastric Cancer Association
Jul 13, 2011·World Journal of Surgery·Takaaki ArigamiShoji Natsugoe
Apr 11, 2012·Immunogenetics·Martin F FlajnikYuko Ohta
May 30, 2013·Proceedings of the National Academy of Sciences of the United States of America·Ruihua ZhaoXingxing Zang
Jun 21, 2013·Nature Communications·Yuwen ZhuLieping Chen
Sep 23, 2014·The Lancet Oncology·Hansjochen WilkeUNKNOWN RAINBOW Study Group
Oct 16, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y YamadaI Hyodo
Dec 19, 2014·Annals of Surgical Oncology·Joshua T ByersYuwen Zhu
Jan 1, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Murali JanakiramXingxing Zang
Feb 6, 2015·CA: a Cancer Journal for Clinicians·Lindsey A TorreAhmedin Jemal
Apr 15, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yanping Xiao, Gordon J Freeman
Jul 5, 2015·Japanese Journal of Clinical Oncology·Megumi HoriUNKNOWN Japan Cancer Surveillance Research Group
Aug 18, 2016·Scientific Reports·Pratistha KoiralaRichard Gorlick
Jul 7, 2017·Molecular Cancer Therapeutics·Ling Ni, Chen Dong
Oct 4, 2017·Journal of Gastric Cancer·Sung Geun KimCho Hyun Park
Oct 11, 2017·Lancet·Yoon-Koo KangLi-Tzong Chen
Jan 24, 2018·Journal for Immunotherapy of Cancer·Jun GongRavi Salgia
Jan 1, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·Y YamadaI Hyodo
Citations
Dec 29, 2019·Journal of Cellular and Molecular Medicine·Can HuXiangdong Cheng
Sep 26, 2019·Human Cell·Li WeiYan Li
Jan 5, 2020·Clinical and Experimental Immunology·C ZhongY Tian
Jun 2, 2020·Frontiers in Immunology·Changgang WangRen Zhao
Jan 13, 2021·Medicine·Jung Mi ByunDae Hoon Jeong
May 9, 2021·Cancer Cell International·Guocai XuBingzhong Zhang
Aug 21, 2021·Biologics : Targets & Therapy·Yituo XuJing Xu